2021–2022 Drug Updates in Solid Tumors

During JADPRO Live 2022, Kirollos Hanna, PharmD, BCPS, BCOP, briefed advanced practitioners on key FDA approvals from late 2021 to late 2022. He described mechanisms of action that are unique across some malignancies, as well as mechanisms of action that clinicians can utilize through an expanded in...

Descripción completa

Detalles Bibliográficos
Autor principal: Hanna, Kirollos
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Harborside Press LLC 2023
Materias:
Meeting Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184837/
https://www.ncbi.nlm.nih.gov/pubmed/37197729
http://dx.doi.org/10.6004/jadpro.2023.14.3.9
_version_ 1785042220493045760
author Hanna, Kirollos
author_facet Hanna, Kirollos
author_sort Hanna, Kirollos
collection PubMed
description During JADPRO Live 2022, Kirollos Hanna, PharmD, BCPS, BCOP, briefed advanced practitioners on key FDA approvals from late 2021 to late 2022. He described mechanisms of action that are unique across some malignancies, as well as mechanisms of action that clinicians can utilize through an expanded indication or across other solid malignancies. Finally, he discussed safety profiles and what advanced practitioners can and should do in monitoring across solid tumors.
format Online
Article
Text
id pubmed-10184837
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Harborside Press LLC
record_format MEDLINE/PubMed
spelling pubmed-101848372023-05-16 2021–2022 Drug Updates in Solid Tumors Hanna, Kirollos J Adv Pract Oncol Meeting Reports During JADPRO Live 2022, Kirollos Hanna, PharmD, BCPS, BCOP, briefed advanced practitioners on key FDA approvals from late 2021 to late 2022. He described mechanisms of action that are unique across some malignancies, as well as mechanisms of action that clinicians can utilize through an expanded indication or across other solid malignancies. Finally, he discussed safety profiles and what advanced practitioners can and should do in monitoring across solid tumors. Harborside Press LLC 2023-04 2023-04-01 /pmc/articles/PMC10184837/ /pubmed/37197729 http://dx.doi.org/10.6004/jadpro.2023.14.3.9 Text en © 2023 Harborside™ https://creativecommons.org/licenses/by-nc-nd/3.0/This article is distributed under the terms of the Creative Commons Attribution Non-Commercial Non-Derivative License, which permits unrestricted non-commercial and non-derivative use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Meeting Reports
Hanna, Kirollos
2021–2022 Drug Updates in Solid Tumors
title 2021–2022 Drug Updates in Solid Tumors
title_full 2021–2022 Drug Updates in Solid Tumors
title_fullStr 2021–2022 Drug Updates in Solid Tumors
title_full_unstemmed 2021–2022 Drug Updates in Solid Tumors
title_short 2021–2022 Drug Updates in Solid Tumors
title_sort 2021–2022 drug updates in solid tumors
topic Meeting Reports
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10184837/
https://www.ncbi.nlm.nih.gov/pubmed/37197729
http://dx.doi.org/10.6004/jadpro.2023.14.3.9
work_keys_str_mv AT hannakirollos 20212022drugupdatesinsolidtumors

Ejemplares similares